Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY (Maribavir) Had Re
Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus (CMV) Infections/Disease Had Reductions in Hospitalizations (34.8%; p=0.021) and Length of Hospital Stay (53.8%; p=0.029) Compared to Those Treated With Conventional Antiviral Therapies1*
Post-Hoc Analyses by Subgroup Showed Shorter Time to First Confirmed CMV DNA Level Less Than the Lower Limit of Quantification ( Data Presented at the 2022 Tandem Meetings and European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Builds Upon the Growing Body of Evidence Supporting LIVTENCITY’s Role in Redefining Treatment for Patients With Post-Transplant CMV Infections1
来源：
作者：
